HZ2, a selective kappa-opioid agonist

CNS Drug Reviews

Volumn 4, Issue 1, 1998, Pages 54-70

  Kogel B ^a   Christoph, T ^a   Friderichs, E ^a   Hennies, H H ^a   Matthiesen, T ^a   Schneider, J ^a   Holzgrabe, U ^b  

^a GRÜNENTHAL GMBH   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Antinociception; HZ2; Pharmacological profile; Selective opioid agonist; Side effects; Structure activity relationship

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; ASIMADOLINE; BUTORPHANOL; ELECTROLYTE; ENADOLINE; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; KAPPA OPIATE RECEPTOR AGONIST; MORPHINE; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NALOXONE; OPIATE AGONIST; PENTAZOCINE; PROSTAGLANDIN E2; RECEPTOR SUBTYPE; SPIRADOLINE;

ANTINOCICEPTION; CARDIOVASCULAR EFFECT; DIURESIS; DOSE RESPONSE; DRUG POTENCY; DRUG SYNTHESIS; DYSPHORIA; HALLUCINATION; HUMAN; INFLAMMATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIPOPHILICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PAIN; PHYSICAL CHEMISTRY; REVIEW; SEDATION; STRUCTURE ACTIVITY RELATION; VOMITING;

EID: 0031657152     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1998.tb00041.x     Document Type: Review

References (71)

1. Bachelard H, Pitre M. Regional haemodynamic effects of μ-, δ-. and κ opioid agonists microinjected into the hypothalamic paraventricular nuclei of conscious, unrestrained rats. Br J Pharmacol 1995;115:613-621.
2. Barber A, Gottschlich R. Novel developments with selective, non peptidic kappa opioid receptor agonists. Exp Opin Invest Drugs 1993;6:1351-1368.
3. Boissier JR, Simon P. La reaction d'exploration chez la souris. Therapie 1962;17:1225-1232.
4. Borsodi A, Benyhe S, Holzgrabe U, Marki A, Nachtsheim C. Structurally novel group of ligands selective for kappa opioid receptors. Reg Peptides 1994;54:27-28.
5. Brandt W, Drosihn S, Haurand M, Holzgrabe U, Nachtsheim C. Search for the pharmacophore in kappa-agonistic diazabicyclo[3.3.1]nonan-9-one-1,5-diesters and arylacetamides. Arch Phorm Pharm Med Chem 1996;329:311-323.
6. Casy AF, Dewar GH. The steric factor in medicinal chemistry - Dissymmetric probes of pharmacological receptors. New York, Plenum Press, 1993:491.
7. Clark CR, Birchmore B, Sharif NA, Hunter JC, Hill RG, Hughes J. PD117302: A selective agonist for the κ opioid receptor. Br J Pharmacol 1988;93:618-626.
8. Codd EE, Shank RP, Schupsky JJ, Raffa RB. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: Structural determinants and role in antinociception. J Pharmacol Exp Ther 1995;274:1263-1270.
9. Crawford CA, McDougall SA, Bolanos CA, Hall S, Berger SP. The effects of the kappa agonist U-50,488 on cocaine-induced conditioned and unconditioned behaviors and fos immunoreactivity. Psychopharmacology 1995;120:392-399.
10. Culpepper-Morgan J, Kreek MJ, Holt PR, LaRoche K, Zhang J, O'Bryan L. Orally administered kappa as well as mu opiate agonists delay gastrointestinal transit time in the guinea pig. Life Sci 1988;42:2073-2077.
11. Costello GF, Main BG, Barlow JJ, Carroll JA, Shaw JS. A novel series of potent and selective agonists at the opioid κ-receptor. Eur J Pharmacol 1988;151:475-478.
12. D'Amour FE, Smith DL. A method for determining loss of pain sensation. J Pharmacol Exp Ther 1941;72:74-78.
13. Dosaka-Akita K, Tortella FC, Holaday JW, Long JB. K opioid agonist U-50,488H antagonizes respiratory effects of κ opioid receptor agonists in conscious rats. Govt Rep Announce Ind 1993;15.
14. Dubuisson D, Dennis SG. The formalin-test: A quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 1977;4:161-174.
15. Dykstra LA, Gmerek DE, Winger G, Woods JH. Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects. J Pharmacol Exp Ther 1987;242:413-420.
16. Eddy NB, Leimbach D. Synthetic analgesics: II. Dithienylbutenyl- and diethienylbutylamines. J Pharmacol Exp Ther 1953;107:385-393.
17. Farid K, Stino R. Divergent selection for pentobarbital-induced sleeping times in mice. Pharmacology 1992;44:257-259.
18. France CP, Medziradsky F, Woods JN. Comparison of kappa opioids in rhesus monkeys: Behavioral effects and receptor binding affinities. J Pharmacol Exp Ther 1994;268:47-58.
19. Frink M, Hennies H-H, Englberger W, Haurand M, Wilffert B. Influence of tramadol on neurotransmitter systems of the rat brain. Arzneim-Forsch/Drug Res 1996;46:1029-1036.
20. Fujibayashi K, Kubota-Watanabe M, Iizuka Y. Effects of R-84760, a selective κ opioid receptor agonist, on nociception, locomotion, and respiration in rats. Arch Int Pharmacodyn Ther 1996;331:153-162.
21. Funada M, Suzuki T, Narita M, Misawa M, Nagase H. Blockade of morphine reward through the activation of kappa opioid receptors in mice. Neuropharmacology 1993;32:1315-1323.
22. Giardina G, Clarke GD, Dondio G, Petrone G, Sbacchi M, Vecchietti V. Selective κ opioid agonists: Synthesis and structure-activity relationships of piperidines incorporating an oxo-containing acyl group. J Med Chem 1994;37:3482-3491.
23. Haller R. Zur Kenntnis substituierter 3, 7-Diaza- und 3-Oxa-7-aza-bicyclo-[3,3,1]-nonanone. Arzneimittelforschung 1965;15:1327-1330.
24. Hansen PE, Morgan BA. Structure-activity relationship in enkephalin peptides. In: Meienhofer J, Udenfried S, eds. The peptides, New York: Academic Press, 1984:269-231.
25. Hayes AG, Birch PJ, Hayward NJ, et al. A series of novel, highly potent, and selective agonists for the κ opioid receptor. Br J Pharmacol 1990;101:944-948.
26. Heidbreder CA, Babovic-Vuksanovic D, Shoaib M, Shippenberg TS. Development of behavioral sensitization to cocaine: Influence of kappa opioid receptor agonists. J Pharmacol Exp Ther 1995;275:150-163.
27. Hendershot LC, Forsaith J. Antagonism of the frequency of phenylquinone-induced writhing in the mouse by weak analgesics and nonalgesics. J Pharmacol Exp Ther 1959;125:237-240.
28. Hunter JC, Leighton GE, Meecham KG, et al. CI-977, a novel and selective agonists for the kappa opioid receptor. Br J Pharmacol 1990;101:183-189.
29. Irwin S. Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia 1968;13:222-2571.
30. Krevsky B, Cowan A, Maurer AH, Butt W, Fisher RS. Effects of selective opioid agonists on feline colonie transit. Life Sci 1991;48:1597-1602.
31. La Regina A, Petrillo P, Sbacchi M, Tavani A. Interaction of U-69-593 with μ-, δ-, and κ-opioid binding sites and its analgesic and intestinal effects in rats. Life Sci 1988;42:293.
32. 3H]U-69593, a highly selective ligand for the opioid K receptor. Eur J Pharmacol 1985;109:281-284.
33. Lason W, Simpson JN, Mcginty JF. The interaction between κ opioid agonist, U-50,488H, and kainic acid: Behavioral and histological assessments. Brain Res 1989;482:333-339.
34. Leander JD. A kappa opioid effect: Increased urination in the rat. J Pharmacol Exp Ther 1983;224:89-94.
35. Leighton GE, Johnson MA, Meecham KG, Hill RG, Hughes J. Pharmacological profile of PD 117302, a selective κ opioid agonist. Br J Pharmacol 1987;92:915-922.
36. Mackay TW, Andrews PLR. A comparative study of the vagal innervation of the stomach in man and the ferret. J Anat 1983;135:449-481.
37. Maisonneuve IM, Archer S, Click SD. U50,488, a kappa opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neuroscience 1994;181:57-60.
38. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine- and nalorphine-like drugs in the non-dependent and morphine dependent chronic spinal dog. J Pharmacol Exp Ther 1976;197:517-532.
39. Macht DI, Barba-Gose J. Two new methods for the pharmacological comparison of insoluble purgatives. J Am Pharm Ass 1931;20:558-564.
40. Martin WR. Pharmacology of opioids. Pharmacol Rev 1984;35:283-323.
41. McLaughlin CR, Tao Q, Abood ME. Analysis of the antinociceptive actions of the κ opioid agonist enandoline (CI-977) in neonatal and adult rats: comparison to κ opioid receptor mRNA ontogeny. Drug Alcohol Depend 1995;38:261-269.
42. Narita M, Suzuki M, Funada M, Misawa M, Nagase H. Blockade of morphine-induced increase in turnover of dopamine on the mesolimbic dopaminergic system by kappa opioid receptor activation in mice. Life Sci 1993;52:397-404.
43. Ohki E, Oida S, Ohashi Y, Yoshida A, Kamoshita K, Takagi H. 3,5-Propanepiperidine derivatives as potential analgesics. Chem Pharm Bull 1974;22:1014-1021.
44. Oka T, Negishi K, Suda M, Matsumiya T, Ueki M. Rabbit vas deferens: A specific bioassay for opioid κ-receptor agonists. Eur J Pharmacol 1981;73:235-236.
45. Peters GR, Ward NJ, Antal EG, Lai PY, Demaar EW. Diuretic actions in man of a selective kappa opioid agonist: U-62,066E. J Pharmacol Exp Ther 1987;240:128-131.
46. Pfeiffer A, Brantl V, Herz A, Emrich HM. Psychotomimesis mediated by κ opiate receptors. Science 1986;233:774-776.
47. Piercey MF, Schroeder LA. A quantitative analgesic assay in the rabbit based on the response to tooth pulp stimulation. Arch Int Pharmacodyn 1980;248:294-304.
48. Porreca F, Burks TF. The spinal cord as a site of opioid effects on gastrointestinal transit in the mouse. J Pharmacol Exp Ther 1983;227:22-27.
49. Przewlocka B, Machelska H, Lason W. κ-Opioid receptor agonists inhibit the pilocarpine-induced seizures and toxicity in the mouse. Eur Neuropsychopharmacol 1994;4:527-533.
50. Ramabadran K, Bansinath M, Turndorf H, Puig MM. Stereospecific inhibition of gastrointestinal transit by κ opioid agonists in mice. Eur J Pharmacol 1988;155:329-331.
51. Randall LO, Selitto JJ. A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn 1957;111:409-419.
52. Reisine T, Pasternak G. Opioid analgesics and antagonists. In: Hardman JG, Limbird LE, eds. The pharmacological basis of therapeutics. New York: McGraw Hill, 1996;521-555.
53. Riviere PJM, Fanner SC, Burks TF, Porreka F. Prostaglandin E2-induced diarrhea in mice: Importance of colonie secretion. J Pharmacol Exp Ther 1991;256:547-552.
54. Saelens JH, Granat FR, Sawyer WK. The mouse jumping test. Simple screening method to estimate the physical dependence capacity of analgesics. Arch Int Pharmacodyn Ther 1971;190:213-218.
55. Salve PS, Hite GJ, Heyman RA, Gianutsos G. 3,7-Diazabicyclane: A new narcotic analgesic. J Med Chem 1986;29:2111-2113.
56. Samhammer A, Holzgrabe U, Haller R. Synthese, Stereochemie and analgetische Wirkung von 3,7-Diazabicyclo[3.3.1]nonan-9-onen und 1,3-Diazaadamantan-6-onen. Arch Pharmacol 1989;322:551-555.
57. Shippenberg TS, Bals-Kubik R, Herz A. Motivational properties of opioids: Evidence that an activation of κ-receptors mediates reinforcement processes. Brain Res 1987;436:234-239.
58. Shippenberg TS, Stein C, Huber A, Millan MJ, Herz A. Motivational effects of opioids in an animal model of prolonged inflammatory pain: Alteration in the effects of κ- but not of μ-agonists. Pain 1988;35:179-186.
59. Shook JE, Pelton JT, Hruby VJ, Burks TF. Peptide opioid antagonist separates peripheral and central opioid antitransit effects. J Pharmacol Exp Ther 1987;243:492-500.
60. Siener T, Ph.D. Thesis. Bonn 1997.
61. Smissman EE, Ruenitz PC. 7-Aza analogs of the analgetic agent azabicyclane. Synthesis and pharmacological analysis. J Med Chem 1976;19:184-186.
62. Suzuki T, Shiozaki Y, Misukawa Y, Misawa M, Nagase H. The role of mu- and kappa opioid receptors in cocaine-induced conditioned place preference. Jpn J Pharmacol 1992;58:435-442.
63. Takemori AE, Ho BY, Naeseth JS, Portoghese PS. Nor-binaltorphimine, a highly selective κ-opioid antagonist in analgesia and receptor binding assays. J Pharmacol Exp Ther 1988;246:255-258.
64. Tavani A, Gambino MC, Petrillo P. The opioid κ-selective compound U-50,488H does not inhibit intestinal propulsion in rats. J Pharm Pharmacol 1984;36:343-344.
65. Thompson PI, Bingham S, Andrews PLR, Patel N, Joel SP, Slevin ML. Morphine-6-gluceronide: A metabolite of morphine with greater emetic potency than morphine in the ferret. Br J Pharmacol 1992;106:3-8.
66. Tortella FC, Robles L, Echevama E, Hunter JC, Hughes J. PD 117302, a selective non-peptide opioid κ-agonist, protects against NMDA and maximal electroshock convulsions in rats. Govt Rep Announce Ind 1990;22.
67. Ukai M, Kameyama T. Multi-dimensional analyses of behavior in mice treated with U50,488H, a purported kappa (non-mu) opioid agonist. Brain Res 1985;337:352-356.
68. Vaupel DB, Cone EJ, Johnson RE, Su TP. Kappa opioid partial agonist activity of the enkephalin-like pentapeptide BW942C based on urination and in vivo studies in humans and animals. J Pharmacol Exp Ther 1990;252:225-234.
69. Von Voigtlander PF, Lahti RA, Ludens JH, U-50,488: A selective and structurally novel non-mu (kappa) opioid agonist. J Pharmacol Exp Ther 1983;224:7-12.
70. Von Voigtlander PF, Lewis RA. Analgesic and mechanistic evaluation of spiradoline, a potent kappa opioid. J Pharmacol Exp Ther 1988;245:259-262.
71. Ward SJ, Takemori AE. Relative involvement of receptor subtypes in opioid-induced inhibition of intestinal motility in mice. Life Sci 1982;31:1267-1270.